RT Journal Article
SR Electronic
T1 Tocilizumab for treatment of mechanically ventilated patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.29.20117358
DO 10.1101/2020.05.29.20117358
A1 Somers, Emily C
A1 Eschenauer, Gregory A
A1 Troost, Jonathan P
A1 Golob, Jonathan L
A1 Gandhi, Tejal N
A1 Wang, Lu
A1 Zhou, Nina
A1 Petty, Lindsay A
A1 Baang, Ji Hoon
A1 Dillman, Nicholas O
A1 Frame, David
A1 Gregg, Kevin S
A1 Kaul, Dan R
A1 Nagel, Jerod
A1 Patel, Twisha S
A1 Zhou, Shiwei
A1 Lauring, Adam S
A1 Hanauer, David A
A1 Martin, Emily
A1 Sharma, Pratima
A1 Fung, Christopher M
A1 Pogue, Jason M
YR 2020
UL http://medrxiv.org/content/early/2020/06/03/2020.05.29.20117358.abstract
AB Background Severe COVID-19 can manifest in rapid decompensation and respiratory failure with elevated inflammatory markers. This presentation is consistent with cytokine release syndrome in chimeric antigen receptor T cell therapy, for which IL-6 blockade is approved treatment.Methods We assessed effectiveness and safety of IL-6 blockade with tocilizumab in a single-center cohort of patients with COVID-19 requiring mechanical ventilation. The primary endpoint was survival probability post-intubation; secondary analyses included an ordinal illness severity scale integrating superinfections. Outcomes in patients who received tocilizumab compared to tocilizumab-untreated controls were evaluated using multivariable Cox regression with propensity score inverse probability weighting (IPTW).Findings 154 patients were included, of whom 78 received tocilizumab and 76 did not. Median follow-up was 47 days (range 28-67). Baseline characteristics were similar between groups, although tocilizumab-treated patients were younger (mean 55 vs. 60 years), less likely to have chronic pulmonary disease (10% vs. 28%), and had lower D-dimer values at time of intubation (median 2.4 vs. 6.5 mg/dL). In IPTW-adjusted models, tocilizumab was associated with a 45% reduction in hazard of death [hazard ratio 0.55 (95% CI 0.33, 0.90)] and improved status on the ordinal outcome scale [odds ratio per 1-level increase: 0.59 (0.36, 0.95)]. Though tocilizumab was associated with an increased proportion of patients with superinfections (54% vs. 26%; p<0.001), there was no difference in 28-day case fatality rate among tocilizumab-treated patients with versus without superinfection [22% vs. 15%; p=0.42].Interpretation In this cohort of mechanically ventilated COVID-19 patients, tocilizumab was associated with a decreased likelihood of death despite higher superinfection occurrence. Randomized controlled trials are urgently needed to confirm these findings.Question Can therapy with the IL-6 receptor antagonist tocilizumab improve outcomes in patients with severe COVID-19 illness requiring mechanical ventilation?Findings In this observational, controlled study of 154 patients, receipt of tocilizumab was associated with a 45% reduction in the hazard of death, despite twice the frequency of superinfection (54% vs 26%), both of which were statistically significant findings.Meaning Tocilizumab therapy may improve survival in patients with COVID-19 illness requiring mechanical ventilation. These results can inform clinical practice pending the results of randomized clinical trials.Competing Interest StatementDisclosures: Dr.Troost reports stock in Proctor & Gamble and General Electric; Dr. Lauring reports being a paid consultant on antivirals for Sanofi and a paid member of a clinical trial steering committee for Baloxavir for Roche; Dr. Martin reports being a paid consultant for Pfizer on RSV and receipt of research funding from Roche.Funding StatementThis work was supported by the National Institutes of Health (NIH/NCATS UL1TR002240; NIH/NHLBI 1K12HL133304 to CMF); the Centers for Disease Control and Prevention (CDC U01IP000974); and an ASTCT New Investigator Award (to JLG). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the NIH, CDC or the Department of Health and Human Services.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained by the Institutional Review Board of the University of Michigan.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData contain PHI and only accessible to IRB-approved investigators